Literature DB >> 10727588

Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.

A Wald1, J Zeh, S Selke, T Warren, A J Ryncarz, R Ashley, J N Krieger, L Corey.   

Abstract

BACKGROUND: Most persons who have serologic evidence of infection with herpes simplex virus (HSV) type 2 (HSV-2) are asymptomatic. Historically, it has been assumed that these persons have less frequent viral reactivation than those with symptomatic infection.
METHODS: We conducted a prospective study to investigate genital shedding of HSV among 53 subjects who had antibodies to HSV-2 but who reported having no history of genital herpes, and we compared their patterns of viral shedding with those in a similar cohort of 90 subjects with symptomatic HSV-2 infection. Genital secretions of the subjects in both groups were sampled daily and cultured for HSV for a median of 94 days.
RESULTS: HSV was isolated from the genital mucosa in 38 of the 53 HSV-2-seropositive subjects (72 percent) who reported no history of genital herpes, and HSV DNA was detected by the polymerase-chain-reaction assay in cultures prepared from genital mucosal swabs in 6 additional subjects. The rate of subclinical shedding of HSV in the subjects with no reported history of genital herpes was similar to that in the subjects with such a history (3.0 percent vs. 2.7 percent). Of the 53 subjects who had no reported history of genital herpes, 33 (62 percent) subsequently reported having typical herpetic lesions; the duration of their recurrences in these subjects was shorter (median, three days vs. five days; P<0.001) and the frequency lower (median, 3.0 per year vs. 8.2 per year; P<0.001) than in the 90 subjects with previously diagnosed symptomatic infection. Only 1 of these 53 subjects had no clinical or virologic evidence of HSV infection.
CONCLUSIONS: Seropositivity for HSV-2 is associated with viral shedding in the genital tract, even in subjects with no reported history of genital herpes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727588     DOI: 10.1056/NEJM200003233421203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  181 in total

1.  Novel approach for specific detection of herpes simplex virus type 1 and 2 antibodies and immunoglobulin G and M antibodies.

Authors:  B Ohana; M Lipson; N Vered; I Srugo; M Ahdut; A Morag
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

2.  Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

Authors:  X Da Costa; M F Kramer; J Zhu; M A Brockman; D M Knipe
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 3.  Recent advances: Sexually transmitted infections.

Authors:  R J Gilson; A Mindel
Journal:  BMJ       Date:  2001-05-12

4.  Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.

Authors:  Alison L Drake; Alison C Roxby; Francisca Ongecha-Owuor; James Kiarie; Grace John-Stewart; Anna Wald; Barbra A Richardson; Jane Hitti; Julie Overbaugh; Sandra Emery; Carey Farquhar
Journal:  J Infect Dis       Date:  2011-12-06       Impact factor: 5.226

Review 5.  Ethics of screening for asymptomatic herpes virus type 2 infection.

Authors:  Ingela Krantz; Gun-Britt Löwhagen; Beth Maina Ahlberg; Tore Nilstun
Journal:  BMJ       Date:  2004-09-11

6.  Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study.

Authors:  Timothy W Schacker; Marcus Conant; Christopher Thoming; Tamara Stanczak; Zengri Wang; Michael Smith
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  New insights on interactions between HIV-1 and HSV-2.

Authors:  Sinéad Delany-Moretlwe; Jairam R Lingappa; Connie Celum
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

8. 

Authors:  A Amor; M Sánchez-Conde
Journal:  Medicine (Madr)       Date:  2009-01-06

9.  [Viral infections].

Authors:  F Galán-Sánchez; C Fernández-Gutiérrez Del Álamo; M Rodríguez-Iglesias
Journal:  Medicine (Madr)       Date:  2014-03-19

10.  The impact of brief messages on HSV-2 screening uptake among female defendants in a court setting: a randomized controlled trial utilizing prospect theory.

Authors:  Alexis M Roth; Barbara Van Der Pol; J Dennis Fortenberry; Brian Dodge; Michael Reece; David Certo; Gregory D Zimet
Journal:  J Health Commun       Date:  2014-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.